Amikacin-containing self-emulsifying delivery systems via pulmonary administration for treatment of bacterial infections of cystic fibrosis patients-Reference-Cited by-同舟云学术

Amikacin-containing self-emulsifying delivery systems via pulmonary administration for treatment of bacterial infections of cystic fibrosis patients

Published:2018-04-01 Issue:7 Volume:13 Page:717-732
ISSN:1743-5889
Container-title:Nanomedicine
language:en
Short-container-title:Nanomedicine

Author:

Hetényi Gergely¹,Griesser Janine¹,Fontana Simon¹,Gutierrez Anja Martinez¹,Ellemunter Helmut²,Niedermayr Katharina²,Szabó Péter³,Bernkop-Schnürch Andreas¹⁴

Affiliation:

1. Thiomatrix Forschungs – und Beratungs GmbH, Innsbruck, Austria

2. Cystic Fibrosis Centre, Department of Child & Adolescent Health, Pediatrics III, Medical University of Innsbruck, Innsbruck, Austria

3. University Pharmacy Department of Pharmacy Administration, Semmelweis University, Budapest, Hungary

4. Department of Pharmaceutical Technology, Institute of Pharmacy, Leopold-Franzens-University, Innsbruck, Austria

Abstract

Aim: The aim of the study was to develop self-emulsifying delivery systems (SEDDS) exhibiting improved permeation rate for pulmonary delivery of amikacin for treatment of cystic fibrosis (CF) patients. Materials & methods: Solubility of amikacin in lipids was improved by hydrophobic ion pairing with sodium myristyl sulfate. The complex was loaded into SEDDS. Drug-release studies were performed and the permeation properties of SEDDS through human CF mucus were examined. Results: A total of 10% complex could be loaded into SEDDS. SEDDS exhibited sustained release. Up to twofold more amounts of amikacin permeated through the CF mucus compared with reference. Conclusion: The developed SEDDS with amikacin may be a promising tool for the treatment of certain bacterial infections of CF patients.

Publisher

Future Medicine Ltd

Subject

Development,General Materials Science,Biomedical Engineering,Medicine (miscellaneous),Bioengineering

Link

https://www.futuremedicine.com/doi/pdf/10.2217/nnm-2017-0307

Reference43 articles.

1. Aspects of pulmonary drug delivery strategies for infections in cystic fibrosis – where do we stand?

2. Nano-antibiotics in chronic lung infection therapy against Pseudomonas aeruginosa

3. Introduction

4. The binding of amikacin to macromolecules from the sputum of patients suffering from respiratory diseases

5. Phase II studies of nebulised Arikace in CF patients withPseudomonas aeruginosainfection

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibiotics modified by hydrophobic ion-pairing – A solution world's problems with resistant bacteria?;Sustainable Materials and Technologies;2023-09

2. Design and Evaluation of Hydrophobic Ion Paired Insulin Loaded Self Micro-Emulsifying Drug Delivery System for Oral Delivery;Pharmaceutics;2023-07-18

3. Hydrophobic ion pairing-based self-emulsifying drug delivery systems: a new strategy for improving the therapeutic efficacy of water-soluble drugs;Expert Opinion on Drug Delivery;2022-11-29

4. Nano-targeted drug delivery approaches for bacterial infections;Emerging Nanomaterials and Nano-Based Drug Delivery Approaches to Combat Antimicrobial Resistance;2022

5. Imine bond formation as a tool for incorporation of amikacin in self-emulsifying drug delivery systems (SEDDS);European Journal of Pharmaceutics and Biopharmaceutics;2021-05